Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MoonLake Immunotherapeutics filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing sonelokimab (SLK) for inflammatory diseases. Form 8-K reports cover operating and financial results, clinical-trial disclosures for SLK programs, FDA meeting updates, Regulation FD communications, material agreements and capital-structure matters involving Class A ordinary shares.
Proxy materials describe annual meeting voting matters, including director elections, auditor ratification, executive compensation and amendments to the 2022 Equity Incentive Plan. The filing record also includes exhibits and registration-related disclosures tied to financings, governance matters and shareholder approvals.
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 3,205,433 Class A ordinary shares of MoonLake Immunotherapeutics, representing 4.35% of the class. All reported shares are held with shared voting and dispositive power; neither reporting person has sole voting or dispositive power.
The ownership percentage is calculated using 73,615,396 Class A ordinary shares outstanding as of May 1, 2026, as stated in MoonLake’s quarterly report. The filing indicates ownership of 5 percent or less of this class of securities and includes customary disclaimers that the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 4,280,624 shares of MoonLake Immunotherapeutics common stock on a Schedule 13G. This position represents 5.3% of the outstanding common stock. T. Rowe Price has sole voting power over 4,111,122 shares and sole dispositive power over 4,280,624 shares, with no shared voting or dispositive power. The firm states that this report should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
MoonLake Immunotherapeutics has an amended Schedule 13G filing reporting that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 7,999,025 Class A ordinary shares of MoonLake Immunotherapeutics. This represents 9.74% of the Class A ordinary shares, based on 82,134,066 shares, which include 81,134,066 common shares outstanding as of June 24, 2026 and 1,000,000 common shares issuable upon exercise of Pre-Funded Warrants held by the reporting persons. All 7,999,025 shares are reported with shared voting and dispositive power and no sole power. The Pre-Funded Warrants are exercisable into common stock but are subject to a 9.99% "Maximum Percentage" limitation, preventing exercises that would increase the holders’ beneficial ownership above 9.99% of the outstanding common stock immediately after any such exercise.
MoonLake Immunotherapeutics filed an automatic shelf registration statement as a well-known seasoned issuer, allowing it to offer from time to time an indeterminate amount of ordinary shares, preference shares, debt securities, warrants and units. A related prospectus supplement establishes an at the market offering of up to $300,000,000 of Class A Ordinary Shares through Leerink Partners as sales agent or principal. Class A Ordinary Shares trade on The Nasdaq Capital Market under the symbol MLTX, with a last reported sale price of $18.26 per share on August 7, 2026. Net proceeds from future issuances are expected to support working capital, advancement of the SLK clinical pipeline, regulatory submissions, commercial planning and general corporate purposes.
MoonLake Immunotherapeutics is a clinical-stage biotech focused on Sonelokimab (SLK) for inflammatory skin and joint diseases. It reported a net loss of $131.5 million for the six months ended June 30, 2026, compared with $96.6 million a year earlier, driven by higher research and development and general and administrative expenses.
The company had $537.0 million in cash, cash equivalents and short-term marketable debt securities and working capital of $524.6 million, and management believes this will fund operations and capital expenditures to mid‑2028. Long‑term debt principal outstanding under its Hercules credit facility was $100.0 million.
Clinically, MoonLake reported strong week‑52 Phase 3 VELA results for SLK in hidradenitis suppurativa, achieving high HiSCR75 and HiSCR100 response rates and improved quality‑of‑life scores, and positive week‑16 primary endpoint results in the Phase 3 IZAR‑1 trial in psoriatic arthritis. The company also raised $189.8 million net in a June 2026 equity offering and continues to expand share‑based incentive programs.
MoonLake Immunotherapeutics reported new clinical and financial updates. The company announced that the Phase 3 IZAR-1 trial of sonelokimab 60 mg with induction in biologic-naïve adults with psoriatic arthritis met all clinical endpoints at Week 16. A total of 42.1% of patients achieved an ACR50 response, with 66.5% achieving ACR20, 41.2% reaching Minimal Disease Activity, and 61% of patients with skin involvement achieving PASI90. Patient-reported and functional measures improved, including a mean HAQ-DI change of -0.427 and an SF-36 PCS score change of 6.54, and the blinded safety analysis showed no new safety signals.
For the quarter ended June 30, 2026, MoonLake reported a net loss of $61.8 million, or $0.84 per share, compared with a net loss of $69.7 million in the prior quarter. Research and development expenses were $50.2 million and general and administrative expenses were $11.4 million, both lower than the previous quarter. The company held $537.0 million in cash, cash equivalents and short-term marketable debt securities as of June 30, 2026, and expects this to fund operations into mid-2028, supplemented by a Hercules Capital debt facility of up to $400 million.
Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, reported the sale of 1,100 Class A ordinary shares at $20.00 per share on July 27, 2026. The shares were owned by JeruCON Beratungsgesellschaft mbH and sold under a Rule 10b5-1 trading plan adopted March 10, 2026. After the transaction, Dr. Reich reported indirect beneficial ownership of 2,711,198 shares through JeruCON and direct ownership of 35,389 shares.
MoonLake Immunotherapeutics reported that JeruCON Beratungsgesellschaft mbH, an entity associated with Chief Scientific Officer Kristian Reich, sold 50,000 and 2,448 Class A ordinary shares on July 21–22, 2026. The 50,000-share block was sold at a weighted average price of $20.0200 per share, in trades between $20.00 and $20.06, and the 2,448-share block at $20.00 per share. Both sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 10, 2026.
Reich may be deemed the indirect beneficial owner of JeruCON’s shares and directly held 35,389 Class A ordinary shares as of July 21, 2026.
MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported that JeruCON Beratungsgesellschaft mbH, an entity whose holdings he may be deemed to beneficially own, sold 43,700 Class A ordinary shares on July 20, 2026 at a weighted average price of $20.09 per share under a Rule 10b5-1 trading plan adopted on March 10, 2026. After the sale, JeruCON held 2,764,746 shares indirectly attributable to him, and he also held 35,389 shares directly.
MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported an indirect sale by JeruCON Beratungsgesellschaft mbH of 16,105 Class A shares on July 15, 2026 under a Rule 10b5-1 trading plan adopted March 10, 2026 at a weighted average price of $20.01 per share, with individual trades from $20.00 to $20.04.
After the sale, JeruCON remained the indirect holder of 2,808,446 Class A ordinary shares, while Reich directly held 35,389 Class A shares.